Financials data is unavailable for this security.
View more
Year on year Innovent Biologics Inc grew revenues 36.21% from 4.56bn to 6.21bn while net income improved from a loss of 2.18bn to a smaller loss of 1.03bn.
Gross margin | 81.69% |
---|---|
Net profit margin | -16.56% |
Operating margin | -16.85% |
Return on assets | -5.38% |
---|---|
Return on equity | -8.84% |
Return on investment | -6.80% |
More ▼
Cash flow in CNYView more
In 2023, Innovent Biologics Inc increased its cash reserves by 170.20%, or 1.73bn. Cash Flow from Financing totalled 2.59bn or 41.69% of revenues. In addition the company generated 147.81m in cash from operations while cash used for investing totalled 998.66m.
Cash flow per share | -0.4466 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 8.37 |
---|---|
Tangible book value per share | 7.52 |
More ▼
Balance sheet in CNYView more
Current ratio | 3.00 |
---|---|
Quick ratio | 2.78 |
Total debt/total equity | 0.289 |
---|---|
Total debt/total capital | 0.2242 |
More ▼